Drug Profile
ST 2427
Alternative Names: ST-2427Latest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator Stanford University
- Developer SiteOne Therapeutics
- Class Analgesics; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers) in USA (IV, Infusion)
- 18 Aug 2021 SiteOne Therapeutics terminates a phase I trial in Postoperative pain (In volunteers) in USA (IV), due to a strategic decision (NCT04475198)
- 04 Mar 2021 Phase-I clinical trials in Postoperative pain (In volunteers) in USA (IV) (NCT04475198)